Issue 15, January 2008 Dear Shareholders Welcome to the first edition of Apollo Life for 2008, our regular newsletter to keep shareholders informed about our latest developments. If you would like any further information, please contact us. Regards John Priest - CEO

HOT TOPIC:

Opening order of AUD$105,000 for Apollo's Ellipse Skin Science range Apollo Applied Science, the over-the-counter (OTC) marketing division of Apollo Life Sciences, recently announced an initial opening order of AUD$105,000 from Myer for its range of Ellipse Skin Science products. The Ellipse Skin Science brand has already generated positive editorial coverage in publications including Marie Claire, Harper's Bazaar and Sunday newspapers.

ALSO IN THIS ISSUE:

Phase I trial of Apollo's Oradel® insulin tablet to begin in mid-2008 Apollo Life Sciences CEO John Priest said the company is on track to become a global leader in the needle-free treatment of diabetes. Sales of Apollo's human proteins double in second half of 2007 Apollo Cytokine Research, a subsidiary of Apollo Life Sciences, announced this week that sales of its human cell-expressed (hcx®) proteins in the second half of 2007 were double that of the first half of the year.

Click here to subscribe

www.apollolifesciences.com

 
Apollo Life Sciences Limited  ASX: AOP
Level 1, 147 Queen Street Beaconsfield NSW 2015 Australia
 
If you would prefer not to receive future email communications from Apollo Life Sciences, please
click here or reply to this message with the word REMOVE in the subject field.
You will receive one additional email confirming your removal.